Bismuth subnitrate is a medication used as an antacid. The use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA.
- Mechanism
- Curator reviewed · 2 references
Based on the findings of a clinical investigation in patients with duodenal ulcer disease and healthy volunteers receiving oral bismuth subnitrate tablets, the protective effects of bismuth subnitrate may be secondary to endogenous mucosal prostaglandin (PGE2) production, which is one of the deficient factors observed in peptic ulcer disease. Antacid neutralizing activity of bismuth subnitrate was demonstrated to have a significant postprandial effect on gastric pH.
- Primary indication
- Indicated for over-the-counter use as an antacid.Curator reviewed
- Formula / weight
- Bi5H9N4O22 · 1461.98 g/mol (avg)
- First approval
- Canada, 1981
- Also known as
- Bismuth hydroxide nitrate oxide · Bismuth nitrate, basic
- Code names
- C.I. 77169
Resolves to
QGWDKKHSDXWPET-UHFFFAOYSA-ESMILES[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[O--].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[Bi+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=OWhat you can answer from here — as of March 06, 2025
Which companies are running trials of Bismuth subnitrate, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account